Technical Analysis for AVEO - AVEO Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 1.94 -1.02% -0.02
AVEO closed down 1.02 percent on Friday, January 18, 2019, on 37 percent of normal volume. It was able to find support at its 50 day moving average.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Down
See historical AVEO trend table...

Date Alert Name Type % Chg
Jan 18 50 DMA Support Bullish 0.00%
Jan 18 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Jan 18 Spinning Top Other 0.00%
Jan 18 Wide Bands Range Expansion 0.00%
Jan 18 Down 3 Days in a Row Weakness 0.00%
Jan 17 50 DMA Support Bullish -1.02%
Jan 17 NR7 Range Contraction -1.02%
Jan 17 Wide Bands Range Expansion -1.02%
Jan 16 50 DMA Support Bullish -2.02%
Jan 16 Wide Bands Range Expansion -2.02%

Older signals for AVEO ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
AVEO Pharmaceuticals, Inc., doing business as AVEO Oncology, operates as a cancer therapeutics company. The company engages in discovering, developing, and commercializing targeted cancer therapies using its Human Response Platform. Its principal product candidate is tivozanib, for which the company has filed a new drug application with the U.S. food and drug administration as a proposed indication for the treatment of patients with advanced renal cell carcinoma (RCC). The company's product pipeline also comprises TAURUS, which is in a Phase II clinical study for the treatment of RCC. In addition, its product pipeline includes Biomarker Assessment of Tivozanib in ONcology program, such as BATON-RCC, a Phase II exploratory biomarker study in patients with advanced RCC; BATON-CRC, a Phase II clinical trial for the first-line therapy in patients with advanced metastatic colorectal cancer; and BATON-BC, a Phase II clinical trial for the treatment of patients with locally recurrent or metastatic triple negative breast cancer. Further, the company has a pipeline of monoclonal antibodies, including Ficlatuzumab, a hepatocyte growth factor inhibitory antibody, which is in Phase II clinical stage for the treatment of non-small cell lung cancer; and AV-203, a monoclonal antibody that targets the ErbB3 receptor and is in Phase I clinical trial for the treatment of solid tumors. AVEO Pharmaceuticals, Inc. has strategic partnerships with Merck & Co., Inc; OSI Pharmaceuticals, Inc.; Kyowa Hakko Kirin; Astellas Pharma Inc.; and Biogen Idec, Inc. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.
Is AVEO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 3.59
52 Week Low 1.4
Average Volume 2,215,770
200-Day Moving Average 2.3489
50-Day Moving Average 1.9248
20-Day Moving Average 1.8435
10-Day Moving Average 2.003
Average True Range 0.1394
ADX 18.82
+DI 17.3619
-DI 22.2404
Chandelier Exit (Long, 3 ATRs ) 1.7218
Chandelier Exit (Short, 3 ATRs ) 1.8182
Upper Bollinger Band 2.2218
Lower Bollinger Band 1.4652
Percent B (%b) 0.63
BandWidth 41.041497
MACD Line 0.013
MACD Signal Line -0.0058
MACD Histogram 0.0188
Fundamentals Value
Market Cap 229.51 Million
Num Shares 118 Million
EPS -0.62
Price-to-Earnings (P/E) Ratio -3.13
Price-to-Sales 80.41
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.06
Resistance 3 (R3) 2.06 2.01 2.04
Resistance 2 (R2) 2.01 1.98 2.02 2.03
Resistance 1 (R1) 1.98 1.96 2.00 1.98 2.03
Pivot Point 1.93 1.93 1.94 1.94 1.93
Support 1 (S1) 1.90 1.90 1.92 1.90 1.85
Support 2 (S2) 1.85 1.88 1.86 1.85
Support 3 (S3) 1.82 1.85 1.84
Support 4 (S4) 1.82